Stem Cells and Derivatives in Inflammatory Bowel Disease: Mechanisms, Sources, and Therapeutic Perspectives

Authors: Cappa Spina, Antonio; Puca, Pierluigi; Troisi, Sara; Petito, Valentina; Masi, Letizia; Migliore, Greta; Pane, Cesare; Parello, Simone; Salvi, Daniele; Pontecorvi, Valerio; Boskoski, Ivo; Spada, Cristiano; Ferrari, Clarissa; Sacchetti, Franco; Potenza, Angelo Eugenio; Caprino, Paola; Sofo, Luigi; Papi, Massimiliano; Parolini, Ornella; Papait, Andrea; Cammarota, Giovanni; Gasbarrini, Antonio; Scaldaferri, Franco; Lopetuso, Loris Riccardo

Source journal: Stem cell reviews and reports (2026-11-20)

DOI: 10.1007/s12015-026-11274-7

Abstract

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic, relapsing disorders of the gastrointestinal tract for which a substantial proportion of patients fail to respond to current therapies, underscoring the need for novel strategies. Mesenchymal stromal cells (MSCs) and their derivatives have emerged as a promising frontier in regenerative medicine, owing to their self-renewal capacity, multilineage differentiation, and potent immunomodulatory properties. MSCs modulate the intestinal microenvironment by suppressing effector T-cell responses, expanding regulatory T (Treg) and B (Breg) cells, polarizing macrophages toward anti-inflammatory phenotypes, reducing pro-inflammatory cytokines, and shaping the gut microbiota. Most of these effects are mediated by paracrine signals carried by the MSC secretome and extracellular vesicles (EVs), which deliver cytokines, microRNAs, and proteins that promote tissue repair, angiogenesis, and resolution of inflammation. Cell-free approaches based on conditioned medium or exosomes offer further advantages over direct cell transplantation, including improved safety, easier standardization, and reduced immunogenicity. MSCs derived from bone marrow, adipose tissue, and perinatal tissues each show distinct biological and therapeutic features. The treatment of complex perianal fistulas in Crohn's disease is the most clinically advanced application, with darvadstrocel demonstrating safety and efficacy in clinical trials. Additional emerging indications include intestinal fibrosis and tissue regeneration. Key challenges remain, including cellular heterogeneity, lack of standardized manufacturing, and optimization of dosing and delivery. Future perspectives point toward a paradigm shift from cell-based therapies to next generation cell-free strategies, including secretome-derived formulations and engineered extracellular vescicles, which may provide safer, more scalable and ultimately disease-modifying therapeutic options for patients with IBD.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.